[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fatigue-post-viral\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fatigue-post-viral":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,74,112,138],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100623301","mechanisms-of-persistent-fatigue-100623301",false,"NCT07394855","Mechanisms of Persistent Fatigue","Mechanisms of Persistent Fatigue (MAP-FAT): A Prospective Observational Cohort Study of Persistent Fatigue Following Epstein-Barr Virus Infection in Adolescents and Young Adults","MAP-FAT","Inclusion Criteria (pertaining to EBV group only):\n\n* EBV infection, laboratory confirmed.\n* First symptoms \\> 3 and \\\u003C 6 weeks away\n\nExclusion Criteria (pertaining to both groups)\n\n* Co-morbidity, including mental illness (seasonal allergy\u002Fasthma is accepted if no signs\u002Fsymptoms)\n* Usage of pharmaceuticals (hormonal contraception and paracetamol\u002Fibuprofen is accepted)\n* Concurrent demanding life event causing fatigue.\n* Disability impacting on daily living.\n* Regular smoking\n* Usage of illicit drugs\n* Pregnancy",true,"ALL","16 Years","39 Years",{"count":22,"type":23},300,"ESTIMATED","OBSERVATIONAL","Persistent fatigue (PF) is a common symptom across countries and cultures, and an important cause of disability and reduced quality of life. Acute infection is a common trigger of PF, as exemplified by the 'Long COVID' phenomenon. Despite substantial burden for the suffering individuals as well as their next-of-kins, the healthcare systems and the economy, PF is an under-researched field, with scarce knowledge of disease mechanisms as well as treatment and preventive measures.\n\nExisting knowledge on PF suggests complex interactions between functional brain processes (as opposed to permanent brain damage), aberrations of the immune system (that normally protects against infection) and the autonomic (or non-voluntary) part of the nervous system (that monitors the internal state of the body and adjusts the function of internal organs). Previous findings have been interpreted in light of two alternative models: A body-to-brain mechanism where disturbances of the immune system are thought to impact on brain functions, and a brain-to-body mechanism where functional brain alteration is regarded the central element whereas aberration of the immune system is seen as a consequence (rather than a cause) mediated through altered activity of the autonomic nervous system.\n\nThe multinational and collaborative Mechanism of Persistent Fatigue (MAP-FAT) project is determined to scrutinize both these potential brain-body interactions in PF. The main objectives are: a) To determine the relationship between PF, activities in certain brain areas, activity in a certain part of the autonomic nervous system (the sympathetic branch), and immunological alterations; b) To determine whether PF is primarily dependent upon the brain's automatic predictions rather than the continuous sensory information mediated to the brain. To achieve these objectives, MAP-FAT will exploit an existing health registry on post-infective fatigue (preparatory part) and conduct a new post-infective cohort study (main part) in which a total of 150 individuals with \"kissing disease\" and 150 healthy controls are followed for six months. Investigations include: a) Clinical and demographic assessment; b) Questionnaire charting; c) Functional and structural imaging of the brain (multimodal brain MRI); d) Assessment of autonomic nervous system activity; e) Deep immunological profiling; and f) Behavioral experiments. The latter are specifically designed to disentangle the relative contributions of the brain's automatic predictions and sensory input for the experience of PF. In addition, one of the experiments includes concurrent functional brain imaging, autonomic nervous system assessment, and immunological profiling during experimental injections of drugs that impact on autonomic activity; this experiment is key for addressing the causal association between brain functions, autonomic activity and immunological disturbance.",[27],"Fatigue Post Viral","RECRUITING","2026-05-19",{"date":31,"type":32},"2026-05-22","ACTUAL",{"date":34,"type":32},"2026-04-28",{"date":36,"type":23},"2027-12",{"name":38,"class":39},"University Hospital, Akershus","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":18,"minAge":48,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":50,"conditions":51,"keywords":58,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":70,"locationsCount":73},"100618493","expanded-access-use-of-human-umbilical-cord-blood-regenecyte-infusion-in-patients-with-chronic-fatigue-of-post-covid-condition-100618493","NCT07332338","Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition","Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion for Patients With Post-COVID Condition","Inclusion Criteria:\n\n* Male or female aged ≥ 18\n* With post-COVID condition\n* Has had a recent (within 7 days) negative SARS-CoV-2 test (an approved PCR (polyermerase chain reaction) or antigen test)\n* Not eligible for participation in any ongoing clinical trials of post-COVID condition with REGENECYTE\n* Able to provide signed informed consent (by the subject or his\u002Fher legally authorized representative)\n* Is willing and able to participate in all aspects of the study, including completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing a written informed consent\n\nExclusion Criteria:\n\n* Neurological disorders prior to COVID-19 diagnosis\n* With pre-existing terminal illness\n* With known immune disease\n* Is pregnant or breastfeeding\n* Is currently participating in another investigational study or has been taking any other investigational product (IP) within the last 4 weeks before screening\n* Has received any vaccination within 3 weeks prior to the first IP infusion or planning to receive vaccination during the treatment period\n* Judged by the investigator to be not suitable for study participation, including but not limited to pre-existing chronic diseases\n* Under the conditions that may increase risk of complications based on the medical judgment of the investigator and the parameters","18 Years","EXPANDED_ACCESS","REGENECYTE® (HPC, Cord Blood (Hematopoietic Progenitor Cell, Cord Blood)) for treatment in patients with post-COVID.",[52,53,54,55,56,57,27],"Post-COVID-19 Condition","Post-COVID Condition","Post-COVID Syndrome","Long COVID","Chronic Fatigue","Chronic Fatigue Symptoms",[55,59,60,61,62,63,64,65],"Post-COVID syndrome","Post-COVID condition","Umbilical cord blood","REGENECYTE","Post-COVID fatigue","Chronic fatigue symptoms","Fatigue post viral","AVAILABLE","2026-03-18",{"date":69,"type":32},"2026-03-23",{"name":71,"class":72},"StemCyte, Inc.","INDUSTRY",2,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":18,"minAge":48,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":93,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":40},"100576556","characterization-treatment-and-long-term-follow-up-of-fatigued-patients-in-primary-care-100576556","NCT06786832","Characterization, Treatment, and Long-term Follow-up of Fatigued Patients in Primary Care","iFAS","Inclusion Criteria:\n\n1. age 18-67\n2. enrollment at a primary care clinic in Region Stockholm\n3. severe, functionally disabling fatigue as a central symptom for at least 3 months\n4. The fatigue has an identifiable start and hence has not been life-long;\n5. The fatigue is not a direct effect of an active disease process motivating another treatment (e.g., hypo-\u002Fhyperthyroidism, anemia, cancer, dementia) or the effect of medication\n6. regular access to a computer and to the Internet\n7. ability to read and write in Swedish.\n8. ability to visit a study center for participation in potential assessments and treatment sessions (maximum 60 minutes) and to take part of written material via the internet.\n\nExclusion Criteria:\n\n1. substance abuse disorder in the past 6 months\n2. Current or past psychosis or bipolar disorder\n3. Primary psychiatric disorder of such severity that it merits evidence-based treatment (e.g., obsessive compulsive disorder, moderate to severe depression, post-traumatic stress disorder, anorexia nervosa)\n4. elevated risk for suicide\n5. deliberate self harm in the past 6-months (e.g., cutting, burning, poisoning);\n6. BMI\\>40\n7. Initiated or changed psychopharmacological medication (e.g., for depression or anxiety disorders) in the past month\n8. ongoing chemotherapy\n9. intellectual disability (e.g., severe autism) that affects ability to work with the treatment\n10. pregnancy\n11. life circumstances that complicate or make treatment impossible (e.g., domestic violence, ongoing legal disputes, disputes with social insurance agency, planed or on-going work capacity assesment regarding permanent work disability pension or planed surgery)\n12. ongoing psychological treatment and\u002For multimodal rehabilitation.\n13. working night shifts","67 Years",{"count":83,"type":23},190,"INTERVENTIONAL",[86],"NA","The overarching purpose of this project is to further the understanding of fatigue as a symptom in primary care patients, and to build evidence for a highly accessible treatment targeting fatigue that can be readily implemented in primary care clinics.\n\nData will be collected within a randomized controlled superiority trial. The primary aim is to evaluate the effectiveness of a transdiagnostic cognitive behavioral therapy (tCBT) for fatigued patients as compared to care as usual (CAU). Primary outcome will be change in fatigue severity (as measured by the Checklist Individual Strengths, fatigue subscale) pre- to post-treatment (6 months), with long-term controlled follow-up after 12 months. A register-based follow-up will be conducted up to 60 months post baseline. Moderators and mechanisms of treatment effect will be investigated with the aim to identify potential subgroups of fatigued individuals across and within diagnostic categories that may respond differently to treatment. Lastly, a health economic evaluation of long-term treatment effects will be conducted, which incorporates much needed detailed mapping of care as usual for fatigued patients.",[89,27,90,91,92],"Fatigue","Exhaustion Disorder","Fatigue Symptom","Fatigue Related to Cancer Treatment",[94,95,96,97,98,89,99,100,101,102],"Psychological treatment","Primary care","cognitive behavioral therapy","blended treatment","randomized controlled trial","burnout","chronic stress","register data","cognitive testing","2026-03-09",{"date":105,"type":32},"2026-03-11",{"date":107,"type":32},"2025-02-06",{"date":109,"type":23},"2033-01",{"name":111,"class":39},"Karolinska Institutet",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":18,"minAge":48,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":84,"phases":123,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":40},"100507685","yoga-versus-health-education-for-the-treatment-of-persistent-fatigue-in-patients-with-post-covid-19-syndrome-100507685","NCT05890599","Yoga Versus Health Education for the Treatment of Persistent Fatigue in Patients With Post COVID-19 Syndrome","Randomized Multicenter Clinical Trial: Yoga Versus Health Education for the Treatment of Persistent Fatigue in Patients With Post COVID-19 Syndrome","YoFaPoCo","Inclusion Criteria:\n\n* Confirmed COVID-19 diagnosis\n* Follow-up symptoms of ≥ 12 weeks\n* Persistent fatigue (scores ≥4 on the binomial Chalder Fatigue Scale).\n* Self-assessment that fatigue was a consequence of COVID-19 disease\n* Age 18-65 years\n\nExclusion Criteria:\n\n* Chronic medical conditions or regular use of medications associated with fatigue\n* Indication of health cause of fatigue other than post-COVID.\n* Indication of other factors as the main cause of fatigue\n* Physical limitations that do not allow participation in the yoga intervention\n* Pregnancy, breastfeeding\n* Concurrent participation in other clinical trials\n* Current yoga practice","65 Years",{"count":122,"type":23},100,[86],"Evaluation of the short- and medium-term effect of a yoga intervention in addition to routine care compared to health education in addition to routine care on fatigue in patients with post covid syndrome.",[126,27],"Post-COVID-19 Syndrome",[89,128],"Covid","2025-07-04",{"date":131,"type":32},"2025-07-10",{"date":133,"type":32},"2023-06-10",{"date":135,"type":23},"2026-03-31",{"name":137,"class":39},"University Hospital Tuebingen",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":48,"enrollmentInfo":144,"targetDuration":146,"studyType":24,"phases":4,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":40},"100388284","covid-19-in-hospitalised-norwegian-children---risk-factors-outcomes-and-immunology-100388284","NCT04335773","COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology","Inclusion Criteria:\n\nSuspected covid-19 infection and age 0-18 years\n\nExclusion Criteria:\n\nAge \\>18 years",{"count":145,"type":23},350,"6 Months","Prospective cohort study of COVID-19 infection among children in Norway.",[149,150,27],"Pediatric Respiratory Diseases","COVID","2022-02-14",{"date":153,"type":32},"2022-02-16",{"date":155,"type":32},"2020-04-03",{"date":157,"type":23},"2030-12-31",{"name":38,"class":39}]